24.7 C
New York
Thursday, June 11, 2026

Tag: enzyme

newssourceFORcompanyinformationcontent1marketreleases

Hi & Fi Asia-China 2025 Shatters Records: Global Engagement Soars

SHANGHAI, July 8, 2025 /PRNewswire/ -- The 2025 edition of Hi & Fi Asia-China, held from24-26 June at NECC, Shanghai, concluded as its most impactful...

Global Industrial Enzyme Markets: Innovation, Impact, and Growth

"The global industrial enzyme market is experiencing rapid growth, driven by advances in biotechnology and increasing demand across sectors like food, biofuels, and textiles....

Best Delta 8 Gummies of 2025: Area 52 Named #1 Edible by Oregon Observer

While competitors push high-THC options, Area 52’s Delta 8 Gummies lead with a balanced, clear-headed experience—now joined by UFO MAX and UFO in the top 3 
While competitors push high-THC options, Area 52’s Delta 8 Gummies lead with a balanced, clear-headed experience—now joined by UFO MAX and UFO in the top 3

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC...

Outlook 2030: Feed Phosphate Market to Surpass $3.22 Billion | Innovation in Animal Health & Precision Feeding Takes Center Stage | The Research Insights

CHICAGO and PUNE, India, July 2, 2025 /PRNewswire/ -- ...

Outlook 2030: Feed Phosphate Market to Surpass $3.22 Billion | Innovation in Animal Health & Precision Feeding Takes Center Stage | The Research Insights

CHICAGO and PUNE, India, July 2, 2025 /PRNewswire/ -- What's Behind the Surge in the US$3.22 Billion Feed Phosphate Market? The Feed Phosphate Market is projected to be...

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

GlucoTru Pro Releases 2025 Health Integrity Update on Blood Pressure & Blood Sugar Balance Innovation

In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions. 
In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.

ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility

LAUSANNE, Switzerland and COPENHAGEN, Denmark, July 01, 2025 (GLOBE NEWSWIRE) -- ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced that the first participant has been included in the company’s Phase 2 clinical trial of its lead candidate RPN-001 (leflutrozole), an orally administered aromatase inhibitor in development for the treatment of male infertility (https://clinicaltrials.gov/study/NCT06993155?term=Leflutrozole&rank=1).

Pet King Brands’ ZYMOX® Designated as a 2025 Vanguard Awards Winner in Eye and Ear Care

Pet Insight Magazine recognizes ZYMOX as a category trailblazer. AUSTIN, Texas, June 30, 2025 /PRNewswire/ -- Pet King Brands, a pioneering leader in veterinarian-recommended enzymatic...

Finding Suggests Treatment Approach for Autoimmune Diseases

NEW YORK, June 30, 2025 /PRNewswire/ -- An engineered protein turns off the kind of immune cells most likely to damage tissue as part...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

- A word from our sponsors -

spot_img
HomeTagsEnzyme

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers